Scarica l'app Stockscreener
33.60
5.04%
1.6405
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$31.96
Aprire:
$32.28
Volume 24 ore:
192.38K
Relative Volume:
0.16
Capitalizzazione di mercato:
$1.92B
Reddito:
$199.89M
Utile/perdita netta:
$52.48M
Rapporto P/E:
39.53
EPS:
0.85
Flusso di cassa netto:
$61.15M
1 W Prestazione:
+1.80%
1M Prestazione:
+14.42%
6M Prestazione:
+189.92%
1 anno Prestazione:
+187.43%
Intervallo 1D:
$31.74
$33.90
Intervallo di 1 settimana:
$31.50
$34.05
Portata 52W:
$5.35
$38.69
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Confronta STOK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
33.56 | 1.83B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.44 | 115.75B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.74 | 80.71B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.94 | 52.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.61 | 52.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.72 | 37.29B | 447.02M | -1.18B | -906.14M | -6.1812 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-18 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Ripresa | Canaccord Genuity | Buy |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Iniziato | Jefferies | Buy |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Iniziato | UBS | Neutral |
| 2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-12-11 | Reiterato | Needham | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-09-29 | Iniziato | Needham | Buy |
| 2019-12-18 | Iniziato | Wedbush | Outperform |
| 2019-11-12 | Iniziato | BTIG Research | Buy |
| 2019-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-15 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Credit Suisse | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Inflation Data: Is Stoke Therapeutics Inc. stock a buy in volatile marketsRate Hike & Weekly Consistent Profit Watchlists - Улправда
Aug Swings: What valuation multiples suggest for Stoke Therapeutics Inc stockQuarterly Portfolio Summary & Technical Buy Zone Confirmation - moha.gov.vn
Corient Private Wealth LLC Invests $7.49 Million in Stoke Therapeutics, Inc. $STOK - MarketBeat
Assenagon Asset Management S.A. Has $21.16 Million Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Is Stoke Therapeutics Inc. stock a buy in volatile marketsJuly 2025 Recap & Verified Momentum Stock Watchlist - Улправда
Stoke Therapeutics (FRA:0GT) EV-to-OCF : 25.91 (As of Dec. 19, 2025) - GuruFocus
Analyst Confidence Surges for Stoke Therapeutics Following Key Data - AD HOC NEWS
Equities Analysts Set Expectations for STOK FY2027 Earnings - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
Biotech leader Stoke Therapeutics offers multiple entries as revenue surges 117% - MSN
Stoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright By Investing.com - Investing.com South Africa
Stoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright - Investing.com India
HC Wainwright & Co. Maintains Stoke Therapeutics (STOK) Buy Recommendation - Nasdaq
Stoke Therapeutics Inc diskutieren - sharewise.com
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $50.00 at HC Wainwright - MarketBeat
STOK: HC Wainwright & Co. Raises Price Target to $50 | STOK Stoc - GuruFocus
Stoke Therapeutics Earnings Notes - Trefis
(STOK) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Stoke Therapeutics: A Deep Dive into Clinical Progress and Market Sentiment - AD HOC NEWS
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? - AOL.com
Redmile Group LLC Cuts Stock Holdings in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 3,978 Shares of Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Sells $433,386.10 in Stock - MarketBeat
Insider Selling Alert: Kaye Edward M. MD Sells Shares of Stoke T - GuruFocus
Stoke Therapeutics Insider Sold Shares Worth $433,385, According to a Recent SEC Filing - marketscreener.com
Dir Kaye Sells 13,430 ($433.4K) Of Stoke Therapeutics Inc [STOK] - TradingView — Track All Markets
Stoke Therapeutics (NASDAQ:STOK) Shares Up 12.4%Time to Buy? - MarketBeat
After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers - Nasdaq
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.1%What's Next? - MarketBeat
Marshall Wace LLP Acquires 168,771 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Officer Allan Files To Sell 3,978 Of Stoke Therapeutics Inc [STOK] - TradingView — Track All Markets
With Stoke Therapeutics Stock Surging, Have You Considered The Downside? - Trefis
Stoke Therapeutics highlights Zorevunersen’s potential at epilepsy meeting - MSN
Biogen, Stoke Therapeutics announce data presentations for zorevunersen - MSN
Stoke Therapeutics, Inc. $STOK Shares Purchased by Franklin Resources Inc. - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Sells $267,723.36 in Stock - MarketBeat
Jonathan Allan Sells 8,785 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Edward Md Kaye Sells 6,453 Shares - MarketBeat
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 1,018 Shares of Stock - MarketBeat
Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)? - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $52,355.52 in Stock - MarketBeat
Allan Jonathan of Stoke Therapeutics sells $306k in shares By Investing.com - Investing.com South Africa
Allan Jonathan of Stoke Therapeutics sells $306k in shares - Investing.com
Stoke Therapeutics Executives Conduct Multiple Stock Sales - TradingView — Track All Markets
Kaye Edward M. MD sells Stoke Therapeutics (STOK) stock for $467k - Investing.com UK
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Fly 36% But Investors Aren't Buying For Growth - 富途牛牛
Biogen (BIIB) Advances Potential Treatment for Dravet Syndrome w - GuruFocus
Zorevunersen shows promise for Dravet syndrome in long-term data By Investing.com - Investing.com South Africa
Stoke Therapeutics Highlights Zorevunersen’s Potential at Epilepsy Meeting - TipRanks
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.02%
3.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):